The regulator’s decision means that RRMM patients who have achieved a complete response or better for at least six months can receive a 1.5mg/kg dose of the BCMA-targeting bispecific antibody every two weeks.
More than 35,000 new cases of multiple myeloma, a currently incurable blood cancer that affects a type of white blood cell called plasma cells, are expected to be diagnosed in the US this year.
